Inovio to present at upcoming scientific conferences

Plymouth meeting, pa. , nov. 6, 2024 /prnewswire/ -- inovio (nasdaq:ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and protect people from hpv-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conferences: 36th international papillomavirus conference (edinburgh, uk; november 12-15) presentation and poster by dr. matthew morrow, vp of translational sciences abstract title: treatment of recurrent respiratory papillomatosis with ino-3107 induces significant enrichment in hallmark interferon alpha, interferon gamma and inflammatory molecular signatures in papilloma tissue of responders poster by dr. jeffrey skolnik, svp of clinical development abstract title: clinical response to ino-3107 treatment for recurrent respiratory papillomatosis is associated with cd4 and cd8 t-cell activity and cytotoxicity in patient airways vaccines summit (boston, ma; november 13-15) keynote presentation by dr. dave liebowitz, svp early-stage clinical development abstract title: dna medicines vaccine platform for both prophylactic and therapeutic applications: case studies in ebola and recurrent respiratory papillomatosis abstracts from these conferences will be made available on inovio's website following each presentation.
INO Ratings Summary
INO Quant Ranking